Form 4: Avidity Biosciences Director Arthur A. Levin Executes Option and Sells Shares

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. on May 20, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 20, 2024, Arthur A. Levin, a director of Avidity Biosciences, Inc., exercised options to purchase 5,000 shares of common stock at a price of $1.24 per share.
• Simultaneously, Levin sold 5,000 shares of Avidity Biosciences common stock at a weighted-average price of $29.8962, with individual sales ranging from $29.23 to $30.36.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 26, 2023.
• Following these transactions, Levin directly owns 14,830 shares and indirectly owns 253,872 shares through a family trust.
• Levin also holds options for 28,323 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are executed under a pre-arranged plan, suggesting no immediate cause for alarm or excitement.

Industry Context

This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of Avidity Biosciences' directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The Rule 10b5-1 trading plan is a common tool used by corporate insiders to avoid accusations of trading on non-public information; many companies such as Eli Lilly and Novo Nordisk have executives that use 10b5-1 plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider trading activity.
• The Rule 10b5-1 plan provides some assurance that the transactions are not based on inside information.

Key Dates